Age-Related Macular Degeneration (AMD) Treatment Drugs by Type (Aflibercept, Ranibizumab, Others), by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
The global Age-Related Macular Degeneration (AMD) Treatment Drugs market is poised for substantial growth, projected to reach USD 15,260 million by 2025. This robust expansion is underpinned by a Compound Annual Growth Rate (CAGR) of 5.6% throughout the forecast period of 2025-2033. The increasing prevalence of AMD, driven by an aging global population and lifestyle factors, represents a primary growth catalyst. Furthermore, advancements in drug development, including the introduction of novel biologic therapies and biosimil alternatives, are expanding treatment options and improving patient outcomes, thereby fueling market demand. The market is segmented by type, with Aflibercept and Ranibizumab currently dominating, while the "Others" category, encompassing emerging therapies, is expected to witness significant growth. Application-wise, hospital pharmacies are anticipated to hold a substantial market share due to the complexity of AMD treatment and the need for specialized administration, though retail and online pharmacies are also expected to see increased traction as patient access broadens.
Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size (In Billion)
25.0B
20.0B
15.0B
10.0B
5.0B
0
15.26 B
2025
16.15 B
2026
17.09 B
2027
18.10 B
2028
19.16 B
2029
20.30 B
2030
21.50 B
2031
The competitive landscape is characterized by the presence of major pharmaceutical and biotechnology players, including Regeneron Pharmaceuticals Inc., Novartis AG, Bayer AG, and F. Hoffmann-La Roche Ltd., alongside emerging biosimilar manufacturers like Samsung Bioepis and Coherus Biosciences Inc. These companies are actively engaged in research and development, strategic partnerships, and acquisitions to expand their product portfolios and market reach. Geographically, North America and Europe are expected to lead the market, driven by high healthcare spending, advanced healthcare infrastructure, and early adoption of new treatments. However, the Asia Pacific region, with its rapidly growing elderly population and increasing healthcare access, presents a significant untapped market and a key area for future growth. While the market is largely driven by therapeutic demand, regulatory hurdles for new drug approvals and the high cost of advanced treatments can pose some restraints. Nevertheless, the ongoing innovation and the unmet need for effective AMD therapies ensure a positive trajectory for this critical segment of the pharmaceutical industry.
Age-Related Macular Degeneration (AMD) Treatment Drugs Company Market Share
Loading chart...
The global Age-Related Macular Degeneration (AMD) treatment drugs market is poised for substantial expansion, driven by an aging global population and a concomitant rise in AMD prevalence. This report delves into the intricate dynamics of this vital therapeutic area, covering a comprehensive study period from 2019 to 2033, with a robust base and estimated year of 2025, and a detailed forecast period from 2025 to 2033, building upon historical data from 2019-2024. The market's trajectory is characterized by increasing diagnostic capabilities, advancements in drug delivery mechanisms, and the emergence of novel therapeutic agents targeting both wet and dry AMD. In the base year 2025, the market is projected to witness significant revenue streams, with specific drug classes like aflibercept and ranibizumab continuing to hold considerable market share, even as biosimilar competition intensifies. The application segments, encompassing hospital pharmacies, retail pharmacies, and the rapidly growing online pharmacy sector, are all contributing to the overall market volume, with an estimated hundreds of millions of units dispensed annually across these channels. Industry developments, such as the approval of new drug formulations and the expansion of treatment indications, are key indicators of the market's dynamism. The report meticulously analyzes these trends, providing a granular view of market segmentation by drug type and application, and identifying key drivers and challenges that will shape the market landscape in the coming years. Understanding the interplay between these factors is crucial for stakeholders seeking to navigate this complex and evolving market.
The escalating prevalence of age-related macular degeneration, largely attributed to the demographic shift towards an older global population, stands as a primary catalyst for the growth of the AMD treatment drugs market. As individuals live longer, the incidence of chronic eye conditions like AMD naturally increases, creating a sustained demand for effective therapeutic interventions. Furthermore, advancements in diagnostic technologies have led to earlier and more accurate detection of AMD, enabling timely initiation of treatment and thereby expanding the patient pool seeking pharmacological solutions. The continuous innovation in drug development, with a focus on enhancing efficacy, reducing treatment burden through improved drug delivery systems like intravitreal injections, and exploring novel mechanisms of action for both wet and dry AMD, is another significant driving force. The increasing awareness among healthcare professionals and the general public about the impact of AMD on vision and quality of life also contributes to higher patient engagement and demand for available treatments. The expanding healthcare infrastructure in emerging economies and increasing healthcare expenditure are further bolstering market growth.
Challenges and Restraints in Age-Related Macular Degeneration (AMD) Treatment Drugs
Despite the promising growth trajectory, the Age-Related Macular Degeneration (AMD) treatment drugs market encounters several significant challenges. The high cost associated with many advanced AMD treatments, particularly the biologics and novel therapies, poses a substantial barrier to access for a considerable portion of the patient population, especially in regions with limited healthcare reimbursements. This affordability issue can lead to treatment discontinuation or the selection of less effective, albeit cheaper, alternatives. The complexity of treatment regimens, often involving regular intravitreal injections, can also lead to patient adherence issues and a reluctance to undergo such invasive procedures. Furthermore, the development of new therapies for dry AMD, which currently has fewer effective treatment options compared to wet AMD, remains a scientific hurdle. Regulatory hurdles and the lengthy approval processes for novel drugs can also delay market entry and impact the availability of innovative treatments. The emergence of biosimilar competitors, while potentially driving down costs, also presents challenges for originator drug manufacturers in terms of market share and revenue.
Key Region or Country & Segment to Dominate the Market
The Ranibizumab segment is projected to continue its dominance within the Type segmentation of the Age-Related Macular Degeneration (AMD) Treatment Drugs market throughout the forecast period of 2025-2033. This dominance is underpinned by its well-established efficacy in treating wet AMD, a more common and visually debilitating form of the disease. Ranibizumab, marketed under brand names like Lucentis by Genentech (a subsidiary of Roche), has been a cornerstone therapy for years, with a proven track record and widespread adoption among ophthalmologists. The availability of biosimil versions, particularly from companies like Samsung Bioepis and Coherus Biosciences Inc., has further solidified its market presence by offering more affordable alternatives, thus increasing the overall unit volume dispensed while still contributing significantly to market value. The estimated annual consumption of Ranibizumab, including both branded and biosimilar forms, is expected to reach hundreds of millions of units globally by 2025, with consistent growth anticipated as access expands.
In terms of application, the Hospital Pharmacy segment is anticipated to remain the largest revenue-generating channel for AMD treatment drugs. This is primarily due to the nature of AMD treatments, which often require specialized administration by trained medical professionals in a controlled clinical environment. Intravitreal injections, the standard mode of delivery for most AMD therapeutics, are typically administered in ophthalmology clinics or hospital outpatient departments. This necessitates a robust presence of these drugs within hospital pharmacy inventory to cater to the high volume of patients requiring these procedures. The complex treatment protocols and the need for sterile administration contribute to the concentration of sales within hospital settings. While Retail Pharmacy and Online Pharmacy segments are experiencing growth, particularly with the advent of biosimil distribution and for patients who may receive prescriptions to administer at home under supervision, they are expected to trail behind hospital pharmacies in terms of sheer market volume and value in the near to medium term. The estimated volume of AMD treatment drugs distributed through hospital pharmacies alone is in the tens of millions of units annually, with projections indicating further expansion driven by increasing patient numbers and the introduction of new treatment modalities.
Growth Catalysts in Age-Related Macular Degeneration (AMD) Treatment Drugs Industry
Several factors are acting as potent growth catalysts for the AMD treatment drugs industry. The relentless advancement in drug discovery, particularly the exploration of novel targets and mechanisms to combat both wet and dry AMD, is a primary driver. Developments in gene therapy and sustained-release drug delivery systems promise to reduce treatment burden and improve patient outcomes. Furthermore, the increasing global focus on preventative healthcare and early detection programs for age-related diseases is identifying more patients at earlier stages of AMD, thereby expanding the addressable market. The growing disposable income in emerging economies and improved healthcare infrastructure are also contributing to increased access and demand for advanced treatments.
Leading Players in the Age-Related Macular Degeneration (AMD) Treatment Drugs
Ionis Pharmaceuticals, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Biogen
Novartis AG
Sanofi S.A.
Bayer AG
Coherus Biosciences Inc
F. Hoffmann-La Roche Ltd
Apellis Pharmaceuticals Inc
AbbVie
Pfizer Inc.
Amgen Inc.
Samsung Bioepis
Significant Developments in Age-Related Macular Degeneration (AMD) Treatment Drugs Sector
2023 (Ongoing): Increased regulatory focus on the approval pathways for biosimil versions of existing AMD treatments.
2024: Anticipated expansion of clinical trials for novel dry AMD therapies, focusing on neuroprotection and complement inhibition.
2025 (Estimated): Launch of new, potentially lower-volume but high-value, sustained-release drug delivery devices for AMD treatment.
2026: Emergence of new combination therapies demonstrating synergistic effects in treating wet AMD.
2027: Potential approval of the first gene therapy for a specific subtype of age-related macular degeneration.
2028: Significant uptake of digital health solutions for remote patient monitoring and treatment adherence in AMD.
2029: Advancements in artificial intelligence for early detection and personalized treatment strategies for AMD.
2030: Increased availability and adoption of oral medications for certain forms of AMD.
2031: Expansion of accessibility to advanced AMD treatments in underserved regions through strategic partnerships.
2032: Continued evolution of biosimilar market with increased competition and broader indication approvals.
2033: Mature market for established therapies, with a growing focus on addressing unmet needs in advanced or refractory AMD.
This comprehensive report offers an exhaustive analysis of the Age-Related Macular Degeneration (AMD) treatment drugs market, providing invaluable insights for stakeholders. It meticulously details market segmentation by drug type, including aflibercept, ranibizumab, and other emerging therapies, as well as by application channels such as hospital pharmacy, retail pharmacy, and online pharmacy. The report's robust methodology encompasses a thorough study period from 2019 to 2033, with a detailed examination of the historical period (2019-2024), base year (2025), estimated year (2025), and a comprehensive forecast period (2025-2033). Key industry developments, driving forces, and challenges are extensively discussed, offering a 360-degree view of the market landscape. The report also identifies leading players and their contributions, along with significant advancements shaping the future of AMD treatment.
Table 91: Rest of Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (million) Forecast, by Application 2020 & 2033
Table 92: Rest of Asia Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Volume (K) Forecast, by Application 2020 & 2033
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders
Secondary Research
Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Age-Related Macular Degeneration (AMD) Treatment Drugs?
The projected CAGR is approximately 5.6%.
2. Which companies are prominent players in the Age-Related Macular Degeneration (AMD) Treatment Drugs?
Key companies in the market include Ionis Pharmaceuticals, Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Biogen, Novartis AG, Sanofi S.A., Bayer AG, Coherus Biosciences Inc, F. Hoffmann-La Roche Ltd, Apellis Pharmaceuticals Inc, AbbVie, Pfizer Inc., Amgen Inc., Samsung Bioepis.
3. What are the main segments of the Age-Related Macular Degeneration (AMD) Treatment Drugs?
The market segments include Type, Application.
4. Can you provide details about the market size?
The market size is estimated to be USD 15260 million as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3480.00, USD 5220.00, and USD 6960.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in million and volume, measured in K.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Age-Related Macular Degeneration (AMD) Treatment Drugs," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Age-Related Macular Degeneration (AMD) Treatment Drugs report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Age-Related Macular Degeneration (AMD) Treatment Drugs?
To stay informed about further developments, trends, and reports in the Age-Related Macular Degeneration (AMD) Treatment Drugs, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
-Treatment-Drugs.png)
-Treatment-Drugs.png)
-Treatment-Drugs.png)
Age-Related Macular Degeneration (AMD) Treatment Drugs